FM Physician Billing

04/12/2013

We are now on LinkedIn connect with us for news and updates.

Welcome to the company profile of FM Physician Billing on LinkedIn. FM Physician Billing knows that the lifeline of your practice depends on being proactive not...

04/09/2013

Oncologists say the reduced funding, which took effect for Medicare on April 1, makes it impossible to administer expensive chemotherapy drugs while staying afloat financially.

04/09/2013

More signatures still needed to help save cancer care!!!!!!!
Please sign this petition!!!!

Sequestration has been applied to Medicare, which is bad news for all seniors, but likely devastating for seniors fighting cancer. This is because the government has decided to apply the sequester payment cut not only to cancer care services, but also to the fixed, pass-through costs of chemotherapy...

04/09/2013

Thousands of Medicare patients nationwide are being turned away by cancer clinics, and the sequester is to blame

04/05/2013

FM Physician Billing would like to welcome New York State Society of Medical Oncologists & Hematologists, Inc to facebook. "LIKE" their page for Oncology news and information.

04/02/2013

Now it is more important than ever to get your practice back on track. Give us a call today!
http://www.medscape.com/viewarticle/781630

Unlike other impending Medicare cuts in the past, this one will not be called off by last-minute Congressional action. Lawmakers are on spring break.

03/20/2013

Just a reminder. Our spring promotion is still in effect!!

03/13/2013

Our new placemat.

03/01/2013

We are looking into the best way to handle Medicare claims after March 1st. More to follow.

The US Senate rejected 2 competing proposals today that would have replaced the "sequester" — $85 billion worth of automatic, across-the-board budget cuts set to take effect March 1.

02/27/2013

02/26/2013

We are starting our “SPRING PROMOTION” early this year.
Don’t miss out on this opportunity!!!!!!
All set-up fees waived from now until May 31st.
Call us today 845-360-5160

02/22/2013

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.